LBRX PE Ratio & Valuation,Is LBRX Overvalued — Intellectia
LBRX Relative Valuation
LBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LBRX is overvalued; if below, it's undervalued.
Historical Valuation
LB Pharmaceuticals Inc(LBRX) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of-4.24.The fair price ofLB Pharmaceuticals Inc(LBRX)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：20.58
Fair
-6.14
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
LB Pharmaceuticals Inc. (LBRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-2.15
EV/EBIT
LB Pharmaceuticals Inc. (LBRX) has a current EV/EBIT of -2.15. The 5-year average EV/EBIT is -4.07. The thresholds are as follows: Strongly Undervalued below -8.55, Undervalued between -8.55 and -6.31, Fairly Valued between -1.84 and -6.31, Overvalued between -1.84 and 0.40, and Strongly Overvalued above 0.40. The current Forward EV/EBIT of -2.15 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
LB Pharmaceuticals Inc. (LBRX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-4.83
P/OCF
LB Pharmaceuticals Inc. (LBRX) has a current P/OCF of -4.83. The 5-year average P/OCF is -3.88. The thresholds are as follows: Strongly Undervalued below -5.59, Undervalued between -5.59 and -4.74, Fairly Valued between -3.03 and -4.74, Overvalued between -3.03 and -2.17, and Strongly Overvalued above -2.17. The current Forward P/OCF of -4.83 falls within the Undervalued range.
-4.90
P/FCF
LB Pharmaceuticals Inc. (LBRX) has a current P/FCF of -4.90. The 5-year average P/FCF is -3.95. The thresholds are as follows: Strongly Undervalued below -5.69, Undervalued between -5.69 and -4.82, Fairly Valued between -3.08 and -4.82, Overvalued between -3.08 and -2.21, and Strongly Overvalued above -2.21. The current Forward P/FCF of -4.90 falls within the Undervalued range.
LB Pharmaceuticals Inc (LBRX) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately 49.25% higher. Relative to its 5-year average P/B ratio of 1.05, the current P/B ratio is about 49.25% higher. LB Pharmaceuticals Inc (LBRX) has a Forward Free Cash Flow (FCF) yield of approximately -4.76%. Compared to its 3-year average FCF yield of -7.23%, the current FCF yield is approximately -34.22% lower. Relative to its 5-year average FCF yield of -7.23% , the current FCF yield is about -34.22% lower.
1.56
P/B
Median3y
1.05
Median5y
1.05
-4.76
FCF Yield
Median3y
-7.23
Median5y
-7.23
Competitors Valuation Multiple
The average P/S ratio for LBRX's competitors is 6.02, providing a benchmark for relative valuation. LB Pharmaceuticals Inc Corp (LBRX) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LBRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LBRX in the past 1 year is driven by Unknown.
Is LB Pharmaceuticals Inc (LBRX) currently overvalued or undervalued?
LB Pharmaceuticals Inc(LBRX)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of-4.24.The fair price of LB Pharmaceuticals Inc(LBRX)is betweentoaccording to relative valuation methord.
What is LB Pharmaceuticals Inc (LBRX) fair value?
LBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of LB Pharmaceuticals Inc (LBRX) is between to according to relative valuation methord.
How does LBRX's valuation metrics compare to the industry average?
The average P/S ratio for LBRX's competitors is 6.02, providing a benchmark for relative valuation. LB Pharmaceuticals Inc Corp (LBRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for LB Pharmaceuticals Inc (LBRX) as of Dec 15 2025?
As of Dec 15 2025, LB Pharmaceuticals Inc (LBRX) has a P/B ratio of 1.56. This indicates that the market values LBRX at 1.56 times its book value.
What is the current FCF Yield for LB Pharmaceuticals Inc (LBRX) as of Dec 15 2025?
As of Dec 15 2025, LB Pharmaceuticals Inc (LBRX) has a FCF Yield of -4.76%. This means that for every dollar of LB Pharmaceuticals Inc’s market capitalization, the company generates -4.76 cents in free cash flow.
What is the current Forward P/E ratio for LB Pharmaceuticals Inc (LBRX) as of Dec 15 2025?
As of Dec 15 2025, LB Pharmaceuticals Inc (LBRX) has a Forward P/E ratio of -6.14. This means the market is willing to pay $-6.14 for every dollar of LB Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for LB Pharmaceuticals Inc (LBRX) as of Dec 15 2025?
As of Dec 15 2025, LB Pharmaceuticals Inc (LBRX) has a Forward P/S ratio of 0.00. This means the market is valuing LBRX at $0.00 for every dollar of expected revenue over the next 12 months.
